Core Viewpoint - The company Haisheng Pharmaceutical (002099.SZ) has announced the initiation of Phase II clinical trials for its innovative therapeutic vaccine NWRD08, targeting HPV-related cervical lesions, marking a significant advancement in cancer treatment in China [1][2]. Group 1: Company Announcement - Haisheng Pharmaceutical received a notification from its subsidiary fund management company, Beijing Guoxin Zhongshu Investment Management Co., Ltd., regarding the participation of Guoxin Haisheng in the investment of Nuo Wei Biotechnology (Wuxi) Co., Ltd. [1] - The Phase II clinical trial for NWRD08 has officially started at several hospitals, including Peking Union Medical College Hospital, with the first subject enrolled and treated [1]. Group 2: Product Details - NWRD08 is the first therapeutic nucleic acid drug in China specifically designed for patients with HPV16/18 positive high-grade squamous intraepithelial lesions (HSIL), aiming to activate specific T-cell immunity to eliminate infected cells [2]. - Unlike preventive HPV vaccines, NWRD08 targets patients already infected with HPV and exhibiting related lesions, offering a new treatment approach [2]. - The Phase I clinical study demonstrated excellent safety and efficacy, with over 80% of subjects achieving either pathological downgrade or HPV virus clearance [2]. - NWRD08 provides a systemic immunotherapy option that is easy to administer and has a low recurrence rate, potentially protecting patients from cervical cancer and treating other HPV-related cancers such as anal, vulvar, and head and neck cancers [2].

Core Viewpoint - The company has announced the initiation of the Phase II clinical trial for NWRD08 injection, a therapeutic vaccine for HPV16/18 positive cervical high-grade squamous intraepithelial lesions (HSIL), marking a significant advancement in cancer treatment in China [1] Group 1: Company Developments - The company has received investment from Beijing Guoxin Haixiang Equity Investment Partnership (Limited Partnership) for its subsidiary, Nuo Wei Biotechnology (Wuxi) Co., Ltd [1] - The Phase II clinical trial for NWRD08 has officially started at Peking Union Medical College Hospital and several other hospitals, with the first subject enrolled and treated [1] Group 2: Product Details - NWRD08 injection is the first domestically developed therapeutic nucleic acid drug targeting HPV16/18 positive HSIL, designed to activate specific T-cell immunity to eliminate infected cells [1] - Unlike preventive HPV vaccines, NWRD08 specifically targets patients already infected with HPV and exhibiting related lesions, aiming to halt disease progression at its source [1] - The therapy allows female patients to retain their cervix compared to traditional surgical removal methods [1]

Core Viewpoint - The announcement highlights the initiation of the Phase II clinical trial for China's first on-demand tumor therapeutic vaccine, NWRD08, developed by Nuowei Biotechnology, with participation from Haixiang Pharmaceutical's investment arm [1] Group 1: Company Developments - Haixiang Pharmaceutical has received a notification from its investment management firm, Beijing Guoxin Zhongshu Investment Management Co., Ltd. [1] - The company’s investment arm, Guoxin Haixiang, is participating in the clinical trial of NWRD08, which has officially started at multiple hospitals, including Peking Union Medical College Hospital [1] - The first subject has been enrolled and administered the vaccine as part of the clinical trial [1] Group 2: Industry Insights - The NWRD08 vaccine represents a significant advancement in the field of oncology, being the first of its kind in China for on-demand treatment [1] - The initiation of this clinical trial may indicate a growing focus on innovative cancer therapies within the biotechnology sector in China [1]

Core Viewpoint - Haishang Pharmaceutical (002099.SZ) announced that its investment partner, Guoxin Haishang, has participated in the clinical trial of the first on-demand therapeutic vaccine for cancer, NWRD08, developed by Nuowei Biotechnology, which has officially started in multiple hospitals including Peking Union Medical College Hospital [1] Group 1: Product Development - NWRD08 is China's first therapeutic nucleic acid drug targeting HPV16/18 positive high-grade squamous intraepithelial lesions (HSIL) that has entered Phase II clinical trials [1] - The drug activates specific T-cell immunity to eliminate infected cells, distinguishing it from preventive HPV vaccines, as it specifically targets patients already infected with HPV and exhibiting related lesions [1] Group 2: Treatment Advantages - NWRD08 aims to activate the body's specific CD8+ T-cell immune response to accurately identify and eliminate cells infected by HPV16/18, fundamentally preventing disease progression [1] - Compared to traditional surgical removal, this therapy allows female patients to retain their complete cervix [1]

浙江海翔药业股份有限公司 关于参投公司创新药 NWRD08 注射液完成Ⅱ期临床首例受试者入 组的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：002099 证券简称：海翔药业 公告编号：2025-058 5、登记号：CTR20253520 二、NWRD08 注射液的其他情况 NWRD08 注射液是我国自主研发的首个针对 HPV16/18 阳性宫颈高级别鳞状上 皮内病变（HSIL）进入Ⅱ期临床阶段的新一代治疗性核酸药物，其通过激活特异 性 T 细胞免疫清除感染细胞。与预防性 HPV 疫苗不同，其专门针对已感染 HPV 并出现相关病变的患者。NWRD08 通过激活机体特异性 CD8+T 细胞免疫应答，精 准识别并清除被 HPV16/18 感染的细胞，从根源上阻止疾病进展。与传统的手术 切除相比，该疗法可使女性患者保留完整的宫颈。 NWRD08 注射液的 I 期临床研究结果显示，NWRD08 展现出优异的安全性，并 能强效激活特异性 T 细胞免疫应答，受试者中实现组织病理学降级或 HPV 病毒清 除的比例超过 80%。NWRD08 注 ...

证券日报网讯12月11日，海翔药业（002099）在互动平台回答投资者提问时表示，截至12月10日公司股 东人数为27495户。 ...

Group 1 - The core announcement is that Haixiang Pharmaceutical (002099) signed a cooperation agreement with the Hangzhou Advanced Research Institute of the University of Science and Technology of China to establish an Advanced Synthesis Technology Industry Research Institute [1] - The research institute will focus on the development and industrialization of pharmaceutical raw materials, intermediates, dyes, and new materials [1] - The total investment for this collaboration amounts to 50 million RMB [1]

Core Insights - The article discusses significant developments in the pharmaceutical and healthcare industry, including leadership changes, regulatory approvals, and strategic collaborations aimed at enhancing treatment options for patients with complex conditions like brain metastases [14][4][12]. Policy Developments - The National Medical Products Administration (NMPA) is focusing on balancing safety and development, emphasizing the importance of legal administration and scientific regulation to protect the legitimate rights of enterprises and promote high-quality industry development [2]. Drug Approvals - Yuandong Biotech received a drug registration certificate for Brivaracetam tablets, marking it as the first generic drug approved under the new registration classification in China. The expected sales for the original drug are approximately 160,000 yuan in the first half of 2025 [4]. - Jiutian Pharmaceutical has received approval for clinical trials of JMHT06 for treating acute gouty arthritis [5]. Capital Market Activities - L'Oréal plans to increase its stake in Galderma by acquiring an additional 10% of shares, which will raise its total ownership to 20% by early 2026. This move includes the nomination of two non-independent directors from L'Oréal to Galderma's board [7]. Industry Collaborations - Baiyang Pharmaceutical is collaborating with multiple medical institutions to enhance treatment for brain metastases, including launching real-world studies with ZAP-X technology and establishing a precision radiotherapy center [12][9].

| | | 12月9日重要公告精选 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 热点 | 骏亚科技 | 应用于人形机器人的相关产品占公司营业收入比重很小 | | | 大业股份 | 从事航天动力系统、天线罩等航天产品研发生产目前净利润规模较小 | | 签约项目 | 水戊奏 | 拟约4亿元建设镁铝合金新材料汽车和机器人零部件智能制造项目 | | 合同中标 | 万马科技 | 预中标5994. 34万元国家电网招标采购项目 | | 股权转让 | 博瑞传播 | 拟6649.02万元收购每经科技合计51%股权 | | 回购 | 惠泰医疗 | 拟斥资2亿元-2.5亿元回购股份 | | 增减持 | 东华测试 | 控股股东及一致行动人拟减持不超过1.99%股份 | | 其他 | 天源迪科 | 董事长陈友被实施留置 | | | 海翔药业 | 与国科大杭州高等研究院签署共建先进合成技术产业研究院合华协议 | 【热点】 骏亚科技(603386.SH)：应用于人形机器人的相关产品占公司营业收入比重很小 大业股份(603278.SH)：主要从事航天动力系统、天线罩等航天产品研发生产，目前净利润规 ...

Core Viewpoint - The collaboration between Haisheng Pharmaceutical and Hangzhou Advanced Research Institute aims to establish an Advanced Synthesis Technology Industry Research Institute, focusing on the development and industrialization of pharmaceutical raw materials, intermediates, dyes, and new materials, with a total investment of 50 million RMB [1][2]. Group 1 - The partnership is based on principles of complementary advantages, market leadership, openness, fairness, and mutual benefit, leveraging both parties' talent, technology, and resource advantages [1]. - The research direction will emphasize green drug synthesis methods and precise modification of active molecules, contributing to sustainable and efficient synthesis in the pharmaceutical sector [1]. - The collaboration is expected to enhance the company's product variety and reserve, reduce costs, and improve product competitiveness while exploring innovative drugs and biopharmaceuticals [2]. Group 2 - The research team from Hangzhou Advanced Research Institute has published significant academic papers in prestigious journals, supporting the development of safe and economical synthesis methods that could revolutionize traditional high-risk processes [1]. - The agreement aims to cultivate high-quality, skilled application-oriented talents to address challenges in research and production, ultimately improving economic efficiency [2]. - The initiative will also explore the integration of artificial intelligence technology in chemical synthesis, optimizing the company's business structure and promoting long-term strategic planning for sustainable development [2].